Search company, investor...

FMI Medical Systems


Incubator/Accelerator | Alive

About FMI Medical Systems

FMI Medical Systems is developing ultra high resolution PET/CT/SPECT diagnostic imaging systems combined with drugs and molecular tracers for earliest detection and monitoring of Alzheimer's, neurodegenerative disorders, and head and neck cancers and breast cancer.

Headquarters Location

526 South Main Street

Akron, Ohio, 44311,

United States


Missing: FMI Medical Systems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: FMI Medical Systems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing FMI Medical Systems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

FMI Medical Systems is included in 3 Expert Collections, including Medical Devices.


Medical Devices

11,693 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health IT

7,901 items

FMI Medical Systems Patents

FMI Medical Systems has filed 10 patents.

The 3 most popular patent topics include:

  • Block ciphers
  • Medical imaging
  • Medical physics
patents chart

Application Date

Grant Date


Related Topics




Block ciphers, Medical imaging, Medical physics, Radiation protection, Spectroscopy


Application Date


Grant Date



Related Topics

Block ciphers, Medical imaging, Medical physics, Radiation protection, Spectroscopy



FMI Medical Systems Frequently Asked Questions (FAQ)

  • Where is FMI Medical Systems's headquarters?

    FMI Medical Systems's headquarters is located at 526 South Main Street, Akron.

  • What is FMI Medical Systems's latest funding round?

    FMI Medical Systems's latest funding round is Incubator/Accelerator.

  • Who are the investors of FMI Medical Systems?

    Investors of FMI Medical Systems include Bounce Innovation Hub.

  • Who are FMI Medical Systems's competitors?

    Competitors of FMI Medical Systems include Dilon Technologies, AltheaDx, Ikonisys, Binx Health, Seno Medical Instruments and 15 more.

Compare FMI Medical Systems to Competitors


MediSpectra, Inc. is a medical device company developing optical detection technology for enhanced accuracy and real-time results in the detection of cancer and other human tissue abnormalities. The technology is based on multimodal optical interrogation of tissue with light. Specifically, a combination of native fluorescence and white light backscatter spectroscopies are coupled with video imaging methods to more accurately detect tissue abnormalities. nnThe company's first product, the LUMA Cervical Imaging System, was designed and developed to improve the detection of high-grade pre-cancerous cervical abnormalities that have the potential of becoming invasive cancer. The LUMA product is intended for use as an adjunct to colposcopy in identifying high grade disease (CIN 2/3+) in patients referred to colposcopy with an ASCUS, LSIL or HSIL+ cervical cytology test result. n

Real Imaging

Real Imaging is developing an imaging solution for breast cancer detection which is both accurate and patient-friendly. Real imaging's MIRA technology will increase correct detection rates and decrease the amount of false diagnoses for women of all ages around the globe.

Microwave Imaging System Technologies (MIST)

Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.

Micrima Logo

Micrima is a Bristol-based company developing a safe, low-cost system to improve the detection of breast cancer. The imaging system captures high-resolution, 3D images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms.


Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.


Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.